Hypertriglyceridemia drugs market seen reaching $10.15 billion by 2030

The global market for hypertriglyceridemia drugs is projected to grow from $7.06 billion in 2025 to $10.15 billion by 2030, driven by rising cardiovascular disease rates, broader lipid testing and new treatment approaches. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Hypertriglyceridemia drugs are used to lower triglycerides and reduce cardiovascular risk. - The market’s growth reflects rising demand for lipid management therapies as heart disease prevention becomes a bigger global priority. - Treatment growth could help reduce complications linked to elevated triglycerides, including heart attacks and strokes.

What happened: - The Business Research Company published its Hypertriglyceridemia Drugs Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will rise from $7.06 billion in 2025 to $7.58 billion in 2026, a 7.4% compound annual growth rate. - The market is expected to reach $10.15 billion by 2030, with a 7.6% CAGR over the forecast period. - The report is available as a free sample. - The full market report is also available online.

The details: - Market growth has been driven by more cardiovascular disease, higher consumption of high-fat diets, stronger awareness of lipid disorders, wider use of statins and fibrates, and better access to advanced lipid diagnostics. - The report expects growth to continue on the back of precision lipid management, new biologic lipid-lowering drugs and more personalized medicine. - Ongoing clinical trials aimed at reducing triglycerides are another growth driver. - Increased healthcare spending on preventive cardiometabolic care is also supporting demand. - Emerging treatment trends include apolipoprotein C-III inhibitors, Angiopoietin-like protein 3 targeted therapies, microsomal triglyceride transfer protein inhibitors for treatment-resistant cases, RNA interference-based therapies and combination regimens using fibrates, omega-3 fatty acids and statins. - North America held the largest market share in 2025. - Asia-Pacific is projected to post the fastest growth during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, and updated technology and trend analysis.

Between the lines: - The market outlook suggests drug development is shifting from broad lipid control toward more targeted and personalized therapies. - The report’s emphasis on advanced biologics and RNA-based approaches points to a more specialized competitive landscape ahead. - Cardiovascular disease trends remain the main demand signal, so market growth is still tied to prevention and chronic care spending. - A UK community health assessment cited in the report said cardiovascular disease deaths rose to 185 in 2023 from 178 in 2022.

What's next: - The report expects precision lipid care, biologic therapies and preventive cardiometabolic spending to keep pushing the market higher through 2030. - Regional growth will likely stay uneven, with North America leading in share and Asia-Pacific expanding fastest. - New pipeline therapies and combination regimens may reshape prescribing patterns if clinical trials continue to show benefit.

The bottom line: - Hypertriglyceridemia drugs are moving from a niche lipid category to a faster-growing part of cardiovascular care, with the market on track to top $10 billion by 2030.